Bapineuzumab, an experimental drug being developed by Pfizer, Elan and Johnson & Johnson, appeared to reduce beta amyloid buildup in the brain by about 25% in Alzheimer's disease patients, according to a study. Researchers used carbon-11-labeled Pittsburgh compound B, an imaging agent that binds with clogged areas of the brain.

Full Story:

Related Summaries